Elraglusib (9-ING-41), a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3, and enhances CD8+ T cell cytolytic killing of melanoma cells.
Olverembatinib (HQP1351), a highly safe and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Evidence of SARS-CoV-2 Spike protein on retrieved thrombi from COVID-19 patients
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL
C3aR costimulation enhances antitumor efficacy of CAR-T through promoting Th17 expansion and memory T phenotype
Prognostic and Therapeutic Biomarker Developments in Multiple Myeloma
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
Learn more about Journal of Hematology & Oncology